AWAK closes one of the largest MedTech fundraise in 2023 in Southeast Asia

AWAK于2023年关闭了东南亚最大的MedTech筹款之一

The Series B round was co-led by new investor Lion X Ventures and long-term investor Vickers Venture Partners, along with other new and existing investors

B系列由新投资者狮子X Ventures和长期投资者Vickers Venture Partners以及其他新投资者和现有投资者共同领导

AWAK's ultra-portable peritoneal dialysis system enables kidney disease patients to undergo dialysis in the comfort of their homes as well as anywhere on the go, offering freedom, time and convenience

AWAK的超便携式腹膜透析系统使肾病患者能够在家中舒适的地方和任何地方进行透析，提供自由，时间和便利

The proceeds will help AWAK to complete the ongoing human pre-pivotal clinical trial, further enhance the products and portfolio, and get closer to a US-based pivotal trial before launching in the US market

这些收益将有助于实现正在进行的人类关键前临床试验，进一步加强产品和组合，并在进入美国市场之前更接近美国的关键试验

SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- AWAK Technologies (AWAK), a pioneering medical technology company focused on dialysis using regeneration technology for end-stage renal disease, today announced it has successfully raised US$20+ million in Series B funding. This milestone not only represents the most substantial MedTech fundraising event in Singapore for 2023, but also one of the largest in Southeast Asia this year.

新加坡，2023年9月13日/PRNewswire/-AWAK Technologies（AWAK），一家专注于使用再生技术进行终末期肾病透析的开创性医疗技术公司，今天宣布在B系列中成功筹集2000多万美元资金。这一里程碑不仅代表了2023年新加坡最重要的MedTech筹款活动，也是今年东南亚最大的活动之一。

The round was co-led by Lion X Ventures and Vickers Venture Partners, both venture capital firms, with other key investors including Advanced MedTech, Eckuity Capital, a US-based healthcare venture capital fund, and an investment office with multibillion dollar assets under management in the healthcare sector..

该轮由Lion X Ventures和Vickers Venture Partners共同领导，两家风险投资公司与其他主要投资者共同领导，包括Advanced MedTech，Eckuity capital，一家美国医疗保健风险投资基金，以及一家拥有数十亿美元资产管理的投资办公室。在医疗保健部门。。

AWAK PD, a wearable and ultraportable peritoneal dialysis (PD) system, offers patients the freedom to undergo dialysis at home as well as anywhere on the go, overcoming the challenge of long hours of stationary therapy and connection to large-size dialysis machines in hospitals and clinics, a challenge currently faced by patients who need dialysis.AWAK's patented technologies not only regenerate and reconstitute waste dialysis fluid into fresh usable fluid thus reducing the amount of dialysis fluid needed by up to 90 per cent, but also enable the miniaturisation of the dialysis machine to fit into a small carry bag; hence reducing the burden of therapy and increasing the patient's quality-of-life by providing them with convenience and time..

AWAK PD是一种可穿戴式超便携式腹膜透析（PD）系统，为患者提供在家中和任何地方进行透析的自由，克服了长时间固定治疗和连接大型透析机的挑战。医院和诊所，目前需要透析的患者面临的挑战。AWAK的专利技术不仅可以将废透析液再生并重新组装成新鲜可用的液体，从而将所需的透析液量减少多达90%，还可以使透析机的小型化适合小型携带袋；因此，通过为他们提供便利和时间来减轻治疗负担并提高患者的生活质量。。

The new proceeds will be used for several key initiatives, including completing AWAK's ongoing human pre-pivotal clinical trial with Singapore General Hospital, making essential enhancements to the ultraportable PD device in anticipation of a final pivotal trial in the US that is expected to commence in 2025.

新的收益将用于几项关键举措，包括在新加坡综合医院完成AWAK正在进行的人体关键前临床试验，对超便携式PD设备进行必要的改进，以期在美国进行最终的关键试验，预计将开始于2025年。

It will also drive the development of new products, including complementary products to promote home dialysis and integrate digital solutions to improve the home-based care of chronic kidney disease patients..

它还将推动新产品的开发，包括促进家庭透析的补充产品和整合数字解决方案，以改善慢性肾病患者的家庭护理。。

Suresha Venkataraya, Chief Executive Officer of AWAK Technologies, said: 'We are delighted to welcome new investors, as well as our existing investors, who believe in our mission to disrupt the kidney care industry by investing in our Series B round, even amidst challenging market conditions. The significant investment in this round, at a higher valuation than our Series A, is a testament to the remarkable progress we've made with our ultraportable device and strategic portfolio expansion.

AWAK Technologies首席执行官Suresha Venkataraya表示：“我们很高兴欢迎新投资者以及我们现有的投资者，他们相信我们的使命是通过投资我们的B系列，甚至在充满挑战的市场条件。这一轮的重大投资估值高于我们的a系列，证明了我们在超便携式设备和战略投资组合扩张方面取得的显着进步。

This investment now propels us towards new and exciting milestones, including further development of our PD product, and an upcoming pivotal clinical trial in the US. On behalf of our dedicated team and board, I extend my heartfelt gratitude to all our investors who share our unwavering commitment to revolutionizing kidney care.'.

这项投资现在推动我们走向新的令人兴奋的里程碑，包括PD产品的进一步开发，以及即将在美国进行的关键性临床试验。我代表我们的专业团队和董事会，对所有分享的投资者表示衷心的感谢。我们对彻底改变肾脏护理的坚定承诺“。

Irene Guo, Co-CEO of Lion X Ventures, said: 'With the dearth of innovation in peritoneal dialysis over the past decades whereas kidney failure is on the rise worldwide, we need new breakthroughs that fundamentally revolutionize dialysis. The next generation dialysis solution is ought to not only be lifesaving but also restore productivity and dignity with convenience and ease for the millions of ESRD patients.

Lion X Ventures的联合首席执行官Irene Guo说：“由于过去几十年腹膜透析缺乏创新而全球肾功能衰竭正在上升，我们需要从根本上改变透析的新突破。下一代透析解决方案不仅应该挽救生命，而且还应该为数百万ESRD患者提供方便和轻松的生产力和尊严。

We are hopeful that AWAK Technologies is poised to debut the world's first wearable kidney device that changes dialysis forever. A strong pipeline of relentless innovation at AWAK in sorbent-based regeneration technology, remote patient monitoring and AI will continue to transform the industry for better and for good, promoting kidney care decentralization and benefiting millions suffering.

我们希望AWAK Technologies有望成为世界上第一个永远改变透析的可穿戴式肾脏设备。在基于吸附剂的再生技术，远程患者监测和人工智能方面，一条强大的无情创新管道将继续改变行业，取得更好的利益，促进肾脏护理分权并使数百万人受益。

Lion X Ventures is thrilled to be part of this journey and looks forward to contributing to AWAK's continued success.'.

狮子X企业很高兴成为这场旅程的一部分，并期待着为AWAK的持续成功做出贡献。

Mhamed Mengad, Board Member of AWAK Technologies and Vice President of Vickers Venture Partners, said: 'We are excited to continue supporting Deep Tech companies like AWAK, as they are making tremendous progress towards bringing life-changing products and solutions to kidney patients. COVID-19 unveiled the intense strain healthcare providers are experiencing and the necessity to complement their capabilities with home therapies and care.

AWAK Technologies董事会成员，Vickers Venture Partners副总裁Mhamed Mengad说：“我们很高兴继续支持像AWAK这样的深度科技公司，因为他们在为肾病患者带来改变生活的产品和解决方案方面取得了巨大进步。新型冠状病毒肺炎揭示了医疗保健提供者正在经历的紧张紧张压力以及在家庭治疗和护理中补充其能力的必要性。

AWAK is uniquely positioned to effectively manage kidney patients and support their transition to in-home care settings.'.

AWAK具有独特的定位，可以有效地管理肾病患者并支持他们向家庭护理环境的过渡。

Abel Ang, Chairman of AWAK Technologies and Group Chief Executive Officer of Advanced MedTech, said: 'AWAK has demonstrated exceptional progress in its goal to disrupt the US$90B global dialysis market. The size of this series B round and valuation step up, despite challenging market conditions, brings AWAK one step closer to transforming the lives of kidney dialysis patients with its revolutionary portable dialysis device.

AWAK Technologies主席兼Advanced MedTech集团首席执行官Abel Ang表示：“AWAK在扰乱900亿美元全球透析市场的目标方面取得了非凡进展。尽管市场条件充满挑战，但这一系列B轮的规模和估值步骤的提升，使其革命性的便携式透析设备更接近于改变肾透析患者的生活。

I am proud of what the team has achieved, and am excited for how AWAK will change kidney care forever.'.

我为团队取得的成就感到骄傲，并且对于唤醒将如何永远改变肾脏护理感到兴奋。

About AWAK Technologies

关于AWAK Technologies

AWAK Technologies Pte. Ltd. is a pioneering, patient-centric medical technology company with a mission to enhance the lives of people with kidney disease and their caregivers by providing solutions to deliver better outcomes and improve their quality of life.

AWAK Technologies Pte。Ltd.是一家开创性的，以患者为中心的医疗技术公司，其使命是通过提供解决方案来提供更好的结果并改善他们的生活质量，从而改善肾病患者及其护理人员的生活。

Headquartered in Singapore with offices in Burbank, California, USA and Bengaluru, India, the company is dedicated to the research, development and marketing of novel, sorbent-based kidney dialysis machine for the treatment of patients with end-stage renal disease. For more information, please visit: www.awak.com.

该公司总部设在新加坡，在美国加利福尼亚州伯班克和印度班加罗尔设有办事处，致力于研究，开发和销售新型吸附剂肾脏透析机，用于治疗终末期肾病患者。欲了解更多信息，请访问：www.awak.com。

Contacts:

联络：

Dennis Wong / Maryanne Lee, Spurwing Communications, +65 6751 2021, [email protected] | Priyanka Arya, AWAK Technologies Pte. Ltd, +65 6950 5011, [email protected]

Dennis Wong/Maryanne Lee，Spurwing Communications，+65 6751 2021，[电子邮件保护]| Priyanka Arya，AWAK Technologies Pte.Ltd，+65 6950 5011，[电子邮件保护]

SOURCE AWAK Technologies

SOURCE AWAK技术